10-Q: Immunocore Q3 2025: KIMMTRAK Sales Surge, Pipeline Advances

Immunocore Holdings plc reported strong 29.2% Q3 revenue growth from KIMMTRAK sales, alongside increased R&D investment and a net loss, as its pipeline progresses.

Summary

• Total revenue for Q3 2025 increased by 29.2% to $103.7 million, up from $80.2 million in Q3 2024.
• Year-to-date (YTD) 2025 revenue from therapy sales grew 30.8% to $295.5 million, compared to $225.9 million in YTD 2024.
• Net loss for Q3 2025 was $0.2 million, a decrease from a net income of $8.7 million in Q3 2024.
• YTD 2025 net loss was $5.5 million, an improvement from a net loss of $27.3 million in YTD 2024.
• Research and development (R&D) expenses increased by 33.7% to $70.6 million in Q3 2025 and by 21.5% to $196.0 million YTD 2025, driven by pipeline progress, particularly autoimmune programs and Tebentafusp trials.
• Selling, general and administrative (SG&A) expenses rose to $39.8 million in Q3 2025 and $122.8 million YTD 2025, supporting global commercial expansion.
• Cash and cash equivalents stood at $498.4 million, with marketable securities at $393.9 million as of September 30, 2025.
• The Independent Data Monitoring Committee (IDMC) recommended 160 mcg as the go-forward dose for brenetafusp in the PRISM-MEL-301 Phase 3 trial for advanced cutaneous melanoma.

Sentiment

Score: 6

Explanation: The company demonstrates strong commercial execution with KIMMTRAK, leading to significant revenue growth. Clinical pipeline advancements, particularly the positive IDMC recommendation for brenetafusp, are encouraging. However, the company continues to incur net losses due to high R&D and SG&A expenses, which are typical for a growth-stage biotech but indicate ongoing cash burn. Geopolitical and tariff risks are also noted as potential headwinds. The overall outlook is cautiously optimistic, balancing commercial success and pipeline progress against continued losses and external uncertainties.

Positives

• Strong revenue growth from KIMMTRAK sales, increasing 29.2% in Q3 2025 to $103.7 million and 30.8% YTD 2025 to $295.5 million.
• KIMMTRAK is now approved in 39 countries and commercially launched in 28, indicating successful global expansion.
• Significant clinical progress with over 2,000 cancer patients treated with ImmTAX product candidates, representing the largest clinical data set for a T cell engager bispecific in solid tumors.
• Positive advancement in the PRISM-MEL-301 Phase 3 trial for brenetafusp, with the IDMC recommending the 160 mcg dose.
• Healthy cash and marketable securities position totaling $892.3 million ($498.4 million cash, $393.9 million marketable securities) as of September 30, 2025, expected to fund operations for at least 12 months.
• YTD 2025 net loss significantly improved to $5.5 million from $27.3 million in YTD 2024.

Negatives

• Reported a net loss of $0.2 million for Q3 2025, compared to a net income of $8.7 million in Q3 2024.
• Increased R&D expenses by 33.7% in Q3 2025 and 21.5% YTD 2025, reflecting ongoing high costs of drug development.
• Increased SG&A expenses by $4.2 million in Q3 2025 and $9.3 million YTD 2025, indicating rising commercial and administrative overheads.
• Interest income decreased by $1.9 million in Q3 2025 and $7.8 million YTD 2025, primarily due to lower interest rates on money market funds and reduced cash balances from marketable securities purchases in 2024.
• Net cash provided by operating activities decreased by $18.1 million YTD 2025 compared to YTD 2024, mainly due to a reduction in accrued expenses and other liabilities.

Risks

• Exposure to economic weakness, inflation, and political instability in non-U.S. economies and markets.
• Challenges with differing and changing regulatory requirements for product approvals across various jurisdictions.
• Potential for reduced protection of intellectual property and proprietary rights in international markets.
• Difficulties in complying with complex and evolving laws, regulations, and court systems in multiple jurisdictions.
• Impact of changes in global regulations, customs, tariffs, and trade barriers, including a proposed 15% tariff ceiling by the U.S. on EU pharmaceuticals, which is expected to increase import costs and reduce margins.
• Fluctuations in non-U.S. currency exchange rates (pound sterling, U.S. dollar, euro) and currency controls.
• Uncertainties and potential adverse effects related to Brexit.
• Differing reimbursement regimes and price controls in certain non-U.S. markets limiting the ability to pass increased costs to customers.
• Negative consequences from changes in tax laws and variable tax treatment of equity awards for international employees.
• Workforce uncertainty in countries with higher labor unrest.
• Potential for litigation or administrative actions from current or former employees or consultants.
• Production shortages due to events affecting raw material supply or manufacturing capabilities abroad.
• Business interruptions stemming from geopolitical actions, including the war in Ukraine, the conflict in the Middle East, global geopolitical tensions, supply chain disruptions, and changes in interest rates and inflation.
• Ongoing military conflicts may impact the ability to conduct clinical trials and commercialize products in affected regions (Ukraine, Russia, Middle East) and have wider global implications.

Future Outlook

The company anticipates continued significant and increasing expenses and operating losses as it advances product candidates through preclinical and clinical development, seeks regulatory approvals, manufactures drug products, expands its intellectual property portfolio, and grows its commercial and administrative support. It expects to generate revenue from KIMMTRAK and potentially other future marketed products, but acknowledges the need for additional funding to support long-term operations and growth strategy. Current cash, cash equivalents, and marketable securities, combined with anticipated KIMMTRAK revenue, are projected to fund operations and capital expenditures for at least the next twelve months. The company intends to explore additional financing opportunities when market terms are favorable.

Management Comments

• "We are a commercial stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases."
• "KIMMTRAK is now approved in 39 countries for the treatment of unresectable or mUM. We have commercially launched KIMMTRAK in 28 countries globally including the United States, Germany and France through September 30, 2025, with further commercial launches planned in additional territories where KIMMTRAK is approved."
• "To date, we have treated over 2,000 cancer patients with KIMMTRAK, tebentafusp, and our other ImmTAX product candidates, which we believe is the largest clinical data set of any T cell engager bispecific in solid tumors and any TCR therapeutic."
• "We expect to continue to incur significant and increasing expenses and to incur operating losses for the foreseeable future, as we advance our product candidates through preclinical and clinical development and seek regulatory approvals, manufacture drug product and drug supply, maintain and expand our intellectual property portfolio, as well as hire additional personnel, pay for further accounting, audit, legal, regulatory and consulting services, and pay costs associated with operating as a public company."
• "We expect that our existing cash and cash equivalents and marketable securities balances, along with anticipated revenue from KIMMTRAK, will enable us to fund our operating expenses and capital expenditure requirements for at least twelve months from the date of filing of this Quarterly Report."

Industry Context

Immunocore operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on immunomodulating medicines using its ImmTAX platform. The strong revenue growth of KIMMTRAK for metastatic uveal melanoma positions it as a leader in a niche oncology market, being the first approved therapy for mUM. The company's expansion into other oncology indications (cutaneous melanoma with brenetafusp), infectious diseases (HBsAg targeting), and autoimmune diseases reflects a broader industry trend of leveraging platform technologies across multiple therapeutic areas. The increasing R&D expenses are typical for a company with a deep clinical and preclinical pipeline, aiming to bring novel therapies to market. The mention of geopolitical tensions and tariffs highlights the globalized nature of pharmaceutical supply chains and the increasing external pressures faced by the industry.

Comparison to Industry Standards

• The company's ImmTAX platform, which includes ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer), is a T cell engager bispecific technology. The claim of having treated over 2,000 cancer patients with ImmTAX product candidates represents a substantial clinical data set for this class of therapeutics, potentially positioning it favorably against other T cell engager developers in solid tumors.
• KIMMTRAK (tebentafusp) is the first approved therapy for metastatic uveal melanoma (mUM), establishing a new standard of care in this specific indication. This is a significant achievement compared to the historical lack of effective treatments for mUM.
• The collaboration with Bristol-Myers Squibb (BMS) for brenetafusp in combination with nivolumab (an established PD-1 inhibitor) in first-line advanced cutaneous melanoma aligns with industry trends of combination therapies to improve efficacy in oncology. Nivolumab is a key immunotherapy in the market, and its inclusion in the trial suggests a strategic approach to leverage existing successful treatments.

Legal Proceedings

• Not currently a party to any material legal proceedings.

Related Party Transactions

• Agreement with the Gates Foundation requires the company to develop, manufacture, and commercialize soluble TCR bispecific therapeutic candidates for neglected diseases (currently HIV) at an affordable price in developing countries. In the event of certain defaults, the Gates Foundation has the right to sell or require the company to buy back its shareholdings, with potential compensation if a change in control occurs at a higher valuation within 12 months.
• Partnered revenue from Medison Pharma Ltd. and Er-Kim Pharmaceuticals Bulgaria EOOD for KIMMTRAK distribution.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity capital raises; share price influenced by revenue growth, pipeline progress, ongoing losses, increasing expenses, and geopolitical/tariff risks.
• Employees: Continued growth in R&D and commercial operations suggests ongoing hiring and retention efforts, supported by share-based compensation plans.
• Customers (Physicians, Patients, Healthcare Payors): Commercial expansion of KIMMTRAK and pipeline development aim to provide transformative medicines; pricing negotiations and reimbursement are critical for patient access.
• Suppliers/Manufacturers: Ongoing manufacturing commitments and potential for increased obligations as the pipeline advances; geopolitical tensions and supply chain disruptions could impact operations.
• Creditors: Convertible senior notes carry fixed interest obligations; the company's liquidity position is strong enough to cover operations for at least 12 months.

Next Steps

• Continue commercialization and marketing of KIMMTRAK, including expanding into additional indications and territories.
• Advance existing and future product candidates through preclinical and clinical development.
• Seek regulatory approvals for product candidates.
• Manufacture drug product and drug supply.
• Maintain and expand the intellectual property portfolio.
• Recruit and retain additional personnel.
• Manage costs associated with operating as a public company.
• Present a poster on IMC-I109V at the 2025 American Association for the Study of Liver Diseases Meeting on November 7, 2025.
• Continue the PRISM-MEL-301 Phase 3 trial for brenetafusp with a 1:1 randomization of HLA-A*02:01 positive, first-line, advanced or metastatic cutaneous melanoma patients to brenetafusp 160 mcg + nivolumab or a control arm.
• Assess the impact of proposed U.S./EU tariffs on import costs and product margins.
• Monitor and adjust business processes to mitigate macroeconomic risks, including economic volatility and currency weakness in countries where products are sold.
• Consider additional financing opportunities when market terms are favorable.
• Pay approximately $65.0 million related to accrued revenue deductions in the three months ending December 31, 2025.

Key Dates

Recommendation

Immunocore is demonstrating strong commercial momentum with KIMMTRAK, evidenced by significant revenue growth and global expansion. The positive clinical update for brenetafusp's Phase 3 trial further de-risks a key pipeline asset. However, the company continues to operate at a net loss due to substantial and increasing R&D and SG&A investments, which are necessary for pipeline advancement and commercial scale-up. While the cash position is healthy for the near term, the explicit mention of potential future capital raises and the identified macroeconomic and geopolitical risks, including tariffs, introduce elements of uncertainty. A "hold" recommendation reflects the balance between the company's promising growth trajectory and pipeline progress against its current unprofitability and external market challenges. Investors should monitor the progress of clinical trials, the impact of commercial expansion on profitability, and the company's ability to manage external risks.

Keywords

Immunocore, KIMMTRAK, uveal melanoma, ImmTAX platform, biotechnology, oncology, clinical trials, brenetafusp, cutaneous melanoma, pharmaceuticals, SEC filing, 10-Q, financial results, R&D, commercialization, drug development, TCR therapeutics, metastatic uveal melanoma, PRAME programs, tebentafusp programs, autoimmune diseases, infectious diseases, tariffs, geopolitical risk